Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEROTOX in degenerative rotator cuff tendinopathy
2024-514074-40-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in shoulder tendinopathy comparing Xeomin with Placebo (2 arms). Primary endpoint: Total SPADI score at 1 month. Planned start Jan 2023; status: authorised.
02
Drugs
botulinum toxin type A
03
Conditions
shoulder tendinopathy
Beyond the preview
Go deeper on 2024-514074-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514074-40-00.